Receptor tyrosine kinases MET and RON as prognostic factors in diffuse large B-cell lymphoma patients receiving R-CHOP

Cancer Science

Volumn 104, Issue 9, 2013, Pages 1245-1251

  Koh, Young Wha ^a   Hwang, Hee Sang ^b   Jung, Se Jin ^a   Park, Chansik ^b   Yoon, Dok Hyun ^b   Suh, Cheolwon ^b   Huh, Jooryung ^b  

^a University of Ulsan College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; KI 67 ANTIGEN; PREDNISONE; PROTEIN RON; PROTEIN TYROSINE KINASE; RITUXIMAB; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; AGED; ALGORITHM; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMORADIOTHERAPY; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; INTENSIVE CARE; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR PROTEIN-TYROSINE KINASES; RETROSPECTIVE STUDIES; VINCRISTINE;

EID: 84883458548     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12215     Document Type: Article

References (45)

1. Moskowitz C. Diffuse large B cell lymphoma: how can we cure more patients in 2012? Best Pract Res Clin Haematol 2012; 25: 41-7.
2. Pileri SA, Agostinelli C, Sabattini E et al. Lymphoma classification: the quiet after the storm. Semin Diagn Pathol 2011; 28: 113-23.
3. Sehn LH. A decade of R-CHOP. Blood 2010; 116: 2000-1.
4. Fu K, Weisenburger DD, Choi WW et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2008; 26: 4587-94.
5. Sehn LH. Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program 2012; 2012: 402-9.
6. Benvenuti S, Comoglio PM. The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol 2007; 213: 316-25.
7. Tajima H, Matsumoto K, Nakamura T. Hepatocyte growth factor has potent anti-proliferative activity in various tumor cell lines. FEBS Lett 1991; 291: 229-32.
8. Shiota G, Rhoads DB, Wang TC, Nakamura T, Schmidt EV. Hepatocyte growth factor inhibits growth of hepatocellular carcinoma cells. Proc Natl Acad Sci U S A 1992; 89: 373-7.
9. Ronen D, Altstock RT, Firon M et al. Met-HGF/SF mediates growth arrest and differentiation in T47D breast cancer cells. Cell Growth Differ 1999; 10: 131-40.
10. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008; 7: 504-16.
11. Masuya D, Huang C, Liu D et al. The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients. Br J Cancer 2004; 90: 1555-62.
12. Aune G, Lian AM, Tingulstad S et al. Increased circulating hepatocyte growth factor (HGF): a marker of epithelial ovarian cancer and an indicator of poor prognosis. Gynecol Oncol 2011; 121: 402-6.
13. Tanimoto S, Fukumori T, El-Moula G et al. Prognostic significance of serum hepatocyte growth factor in clear cell renal cell carcinoma: comparison with serum vascular endothelial growth factor. J Med Invest 2008; 55: 106-11.
14. Chen YQ, Zhou YQ, Angeloni D, Kurtz AL, Qiang XZ, Wang MH. Overexpression and activation of the RON receptor tyrosine kinase in a panel of human colorectal carcinoma cell lines. Exp Cell Res 2000; 261: 229-38.
15. Wang MH, Wang D, Chen YQ. Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase. Carcinogenesis 2003; 24: 1291-300.
16. Bardella C, Costa B, Maggiora P et al. Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression. Cancer Res 2004; 64: 5154-61.
17. Wang MH, Kurtz AL, Chen Y. Identification of a novel splicing product of the RON receptor tyrosine kinase in human colorectal carcinoma cells. Carcinogenesis 2000; 21: 1507-12.
18. Thangasamy A, Rogge J, Ammanamanchi S. Regulation of RON tyrosine kinase-mediated invasion of breast cancer cells. J Biol Chem 2008; 283: 5335-43.
19. Catenacci DV, Cervantes G, Yala S et al. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther 2011; 12: 9-46.
20. Uddin S, Hussain AR, Ahmed M et al. Inhibition of c-MET is a potential therapeutic strategy for treatment of diffuse large B-cell lymphoma. Lab Invest 2010; 90: 1346-56.
21. Renne C, Willenbrock K, Martin-Subero JI et al. High expression of several tyrosine kinases and activation of the PI3K/AKT pathway in mediastinal large B cell lymphoma reveals further similarities to Hodgkin lymphoma. Leukemia 2007; 21: 780-7.
22. Kawano R, Ohshima K, Karube K et al. Prognostic significance of hepatocyte growth factor and c-MET expression in patients with diffuse large B-cell lymphoma. Br J Haematol 2004; 127: 305-7.
23. Chen Q, Seol DW, Carr B, Zarnegar R. Co-expression and regulation of Met and Ron proto-oncogenes in human hepatocellular carcinoma tissues and cell lines. Hepatology 1997; 26: 59-66.
24. Cheng HL, Liu HS, Lin YJ et al. Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. Br J Cancer 2005; 92: 1906-14.
25. Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-86.
26. Choi WW, Weisenburger DD, Greiner TC et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009; 15: 5494-502.
27. Nakajima M, Sawada H, Yamada Y et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999; 85: 1894-902.
28. Kammula US, Kuntz EJ, Francone TD et al. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett 2007; 248: 219-28.
29. Ramirez R, Hsu D, Patel A et al. Over-expression of hepatocyte growth factor/scatter factor (HGF/SF) and the HGF/SF receptor (cMET) are associated with a high risk of metastasis and recurrence for children and young adults with papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2000; 53: 635-44.
30. Nakopoulou L, Gakiopoulou H, Keramopoulos A et al. c-met tyrosine kinase receptor expression is associated with abnormal beta-catenin expression and favourable prognostic factors in invasive breast carcinoma. Histopathology 2000; 36: 313-25.
31. Hui MK, Lai KK, Chan KW et al. Prognostic significance of phosphorylated RON in esophageal squamous cell carcinoma. Med Oncol 2012; 29: 1699-706.
32. Accordi B, Pillozzi S, Dell'Orto MC et al. Hepatocyte growth factor receptor c-MET is associated with FAS and when activated enhances drug-induced apoptosis in pediatric B acute lymphoblastic leukemia with TEL-AML1 translocation. J Biol Chem 2007; 282: 29384-93.
33. Shen K, Novak RF. Fas-signaling and effects on receptor tyrosine kinase signal transduction in human breast epithelial cells. Biochem Biophys Res Commun 1997; 230: 89-93.
34. Wang X, DeFrances MC, Dai Y et al. A mechanism of cell survival: sequestration of Fas by the HGF receptor Met. Mol Cell 2002; 9: 411-21.
35. Di Renzo MF, Olivero M, Giacomini A et al. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res 1995; 1: 147-54.
36. Di Renzo MF, Olivero M, Martone T et al. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 2000; 19: 1547-55.
37. Peace BE, Hughes MJ, Degen SJ, Waltz SE. Point mutations and overexpression of Ron induce transformation, tumor formation, and metastasis. Oncogene 2001; 20: 6142-51.
38. Senchenko VN, Liu J, Loginov W et al. Discovery of frequent homozygous deletions in chromosome 3p21.3 LUCA and AP20 regions in renal, lung and breast carcinomas. Oncogene 2004; 23: 5719-28.
39. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4: 915-25.
40. Lai AZ, Abella JV, Park M. Crosstalk in Met receptor oncogenesis. Trends Cell Biol 2009; 19: 542-51.
41. Danilkovitch A, Donley S, Skeel A, Leonard EJ. Two independent signaling pathways mediate the antiapoptotic action of macrophage-stimulating protein on epithelial cells. Mol Cell Biol 2000; 20: 2218-27.
42. Follenzi A, Bakovic S, Gual P, Stella MC, Longati P, Comoglio PM. Cross-talk between the proto-oncogenes Met and Ron. Oncogene 2000; 19: 3041-9.
43. Lee WY, Chen HH, Chow NH, Su WC, Lin PW, Guo HR. Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients. Clin Cancer Res 2005; 11: 2222-8.
44. Lee CT, Chow NH, Su PF, Lin SC, Lin PC, Lee JC. The prognostic significance of RON and MET receptor coexpression in patients with colorectal cancer. Dis Colon Rectum 2008; 51: 1268-74.
45. Uddin S, Hussain AR, Ahmed M et al. Inhibition of fatty acid synthase suppresses c-Met receptor kinase and induces apoptosis in diffuse large B-cell lymphoma. Mol Cancer Ther 2010; 9: 1244-55.